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Multiple myeloma (MM) is characterized by the clonal prolifer-
ation of malignant plasma cells in the bone marrow (BM)
associated with bone lesion, renal failure and immunodeﬁciency.
Despite conventional therapies including high-dose chemotherapy
with stem cell transplantation, it remains incurable due to both
intrinsic and acquired drug resistance. Novel biologically-based
treatments targeting MM cells as well as the BM microenviron-
ment, including thalidomide, lenalidomide and Bortezomib, offer
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Summary
This study investigated the biological signiﬁcance of the inhibition of fatty
acid synthase (FAS) in multiple myeloma (MM) using the small molecule
inhibitor Cerulenin. Cerulenin triggered growth inhibition in both MM cell
lines and MM patient cells, and overcame the survival and growth advantages
conferred by interleukin-6, insulin-like growth factor-1, and bone marrow
stromal cells. It induced apoptosis in MM cell lines with only modest
activation of caspase -8, -9, -3 and PARP; moreover, the pan-caspase
inhibitor Z-VAD-FMK did not inhibit Cerulenin-induced apoptosis and
cell death. In addition, treatment of MM cells with Cerulenin primarily
up-regulated apoptosis-inducing factor/endonuclease G, mediators of cas-
pase-independent apoptosis. Importantly, Cerulenin induced endoplasmic
reticulum stress response via up-regulation of the Grp78/IRE1a/JNK
pathway. Although the C-Jun-NH2-terminal kinase (JNK) inhibitor
SP600215 blocked Cerulenin-induced cytotoxicity, it did not inhibit
apoptosis and caspase cleavage. Furthermore, Cerulenin showed synergistic
cytotoxic effects with various agents including Bortezomib, Melphalan and
Doxorubicin. Our results therefore indicate that inhibition of FAS by
Cerulenin primarily triggered caspase-independent apoptosis and JNK-
dependent cytotoxicity in MM cells. This report demonstrated that inhibition
of FAS has anti-tumour activity against MM cells, suggesting that it
represents a novel therapeutic target in MM.
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2004; Richardson et al, 2004; Hideshima et al, 2007).
Fatty acid synthesis occurs inall living organism and provides for
essential components of both biological membranes and energy
storage. Fatty acid synthase (FAS) is a multifunctional enzyme that
catalyzes the terminal steps in the synthesis of the 16-carbon fatty
acid palmitate in cells (Wakil, 1989; Asturias et al, 2005). In normal
cells, FAS expression levels are relatively low, since fatty acid is
generallysuppliedbydietaryfattyacid.Incontrast,FASisexpressed
at signiﬁcantly higher levels in a variety of human cancers including
breast,colon,ovary,lung,prostateandothers(Milgraumet al,1997;
Kuhajda, 2000, 2006; Pizer et al, 2001; Baron et al, 2004; Menendez
& Lupu, 2007). Moreover, several reports have shown that FAS
expression levels correlate with tumour progression, aggressiveness
and metastasis (Kuhajda, 2000, 2006; Rossi et al, 2003). For
example, FAS expression levels are predictive of poor prognosis in
breast and prostate cancer (Kuhajda, 2006). As FAS has been
strongly linked to tumour cell proliferation (Kuhajda, 2000) and is
preferentially expressed in cancer cells, it may represents an
attractive target for novel anticancer therapy (Kuhajda, 2006;
Menendez & Lupu, 2007). Importantly, Cerulenin, a speciﬁc
inhibitor of FAS derived from a natural product of Cephalosporium
caerulens,inhibitstumourgrowthandinducesapoptosisinavariety
of cancer cell lines (Pizer et al, 1996a,b; Heiligtag et al, 2002). It
irreversibly inhibits FAS by binding covalently to cysteine at the
active site of the b keto acyl synthase moiety, which catalyzes the
condensation reaction between the elonging fatty acid chain and
eachsuccessiveacetylormalonylresidue.OtherFASinhibitors,such
asC75andorlistat,alsoshowantitumouractivityinvitroandinvivo
(Kuhajda et al, 2000; Gabrielson et al, 2001; Kridel et al, 2004). The
effect of FAS inhibitor on cancer is further veriﬁed by RNA
interferencetodownregulateFASinprostateandbreastcancercells,
which induces apoptosis (De Schrijver et al, 2003; Bandyopadhyay
et al, 2006).
ThisstudydeterminedthebiologicalsigniﬁcanceoftargetingFAS
in MM using the small molecule inhibitor Cerulenin. Cerulenin
triggers growth inhibition in both MM cell lines and patient MM
cells, as well as overcomes the survival and growth advantages
conferredbyinterleukin-6(IL-6),insulin-likegrowthfactor-1(IGF-
1) and bone marrow stromal cells (BMSC). It induces apoptosis in
MM cell lines with only modest activation of caspase -8, -9, -3 and
Poly (ADP-ribose) polymerase (PARP); moreover, the pan-caspase
inhibitor Z-VAD-FMK does not inhibit Cerulenin-induced apop-
tosis and cell death. During Cerulenin-induced apoptosis, both
apoptosis-inducing factor (AIF) and endonuclease G (Endo G) are
released from the mitochondria to cytosol, suggesting that Cerule-
nin triggers apoptosis, at least in part, via a caspase-independent,
AIF/Endo G pathway. Importantly, Cerulenin also induces endo-
plasmic reticulum (ER) stress response via up-regulation of Grp78/
IRE1a/JNK pathway. Although the C-Jun-NH2-terminal kinase
(JNK) inhibitor, SP600215, blocks Cerulenin-induced cytotoxicity,
it does not inhibit apoptosis and caspase cleavage triggered by
Cerulenin. Importantly, Cerulenin triggers synergistic cytotoxicity
with various agents including Bortezomib, Melphalan and Doxo-
rubicin, which induce apoptosis via activation of caspases. Our
resultsthereforeindicatethatinhibitionofFASbyCerulenintriggers
primarily caspase-independent apoptosis and JNK-dependent cell
death in MM, conﬁrming that FAS represents a novel therapeutic
target in MM.
Materials and methods
Reagents
TheFASinhibitor,Cerulenin,wasprovidedbyEMDchemicals(San
Diego, CA, USA). Cerulenin, (2R, 3S)-2,3-epoxy-4-oxo-7,10-trans,
trans-dodecadienamide (C12H17NO3), a natural product of Ceph-
alosporium caerulens, is a speciﬁc inhibitor of FAS enzyme across a
broad phylogenetic spectrum (Vance et al, 1972; Omura, 1976;
Moche et al, 1999). It was dissolved in dimethyl sulphoxide
(DMSO) at 50 mmol/l stock solution and stored at )20 C. Recom-
binant human IL-6, IGF-1 (R&D Systems, Minneapolis, MN, USA)
were reconstituted with sterile phosphate-buffered saline (PBS)
containing 0Æ1% bovine serum albumin (BSA). Pan-caspase inhib-
itor Z-VAD-FMK (Bachem, Bubendorf, Switzerland) was dissolved
in methanol, stored at )20 C, and used at 25 lmol/l. JNK inhibitor
SP600215 (Calbiochem, San Diego, CA, USA) was stored at )20 C,
and used at 5–10 lmol/l. Tunicamycin (Sigma Chemical, St Louis,
MO, USA) was dissolved in DMSO at 10 mg/ml stock solution and
stored at 4 C, and used at 5 lg/ml. Melphalan and Doxorubicin
were purchased from Sigma Chemical. Bortezomib was obtained
from Millenium Pharmaceuticals Inc., Cambridge, MA, USA.
Cells
Dex-sensitive (MM.1S) and resistant (MM.1R) human MM cell
lines were kindly provided by Dr Steven Rosen (Northwestern
University, Chicago, IL, USA). RPMI-8226 and U266 human MM
cell lines were obtained from American Type Culture Collection
(Manassas, VA, USA). RPMI 8226-Dox40 (Doxorubicin-resistant)
and RPMI 8226-LR5 (Mel-resistant) human MM cells were kindly
provided by Dr William Dalton (Lee Mofﬁtt Cancer Center,
Tampa, FL, USA). OPM1 and OPM2 were provided from by Dr P.
Leif Bergsagel (Mayo Clinic, Tucson, AZ, USA). Each of these cell
lines were cultured in RPMI-1640 containing 10% fetal bovine
serum (FBS; Sigma Chemical), 2 lmol/l l-glutamine, 100 U/ml
penicillin and 100 lg/ml streptomycin (GIBCO, Grand Island,
NY, USA). Fresh peripheral blood mononuclear cells (PBMNC)
obtained from three healthy volunteers were separated from
heparinized peripheral blood by Ficoll-Hypaque (Pharmacia,
Piscataway, NJ, USA) density sedimentation.
Primary MM cells and BMSCs from MM patients, and
plasma cells from healthy volunteers
Tumour cells freshly isolated from MM patients and plasma cells
from healthy volunteers (>90% CD138
+) were puriﬁed by CD138
positive selection using CD138 (Syndecan-1) Micro Beads and the
Auto MACS magnetic cell sorter (Miltenyi Biotec Inc., Auburn,
CA, USA). BM mononuclear cells separated by Ficoll-Hypaque
were cultured in Dulbecco’s modiﬁed Eagles medium (Sigma
Chemical) supplemented with 15% heat-inactivated FBS, 2 lmol/l
l-glutamine, 100 U/ml penicillin and 100 lg/ml streptomycin for
3–6 weeks to generate BMSCs. Approval for these studies was
Y. Okawa et al
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Review Board. Informed consent was obtained from all patients in
accordance with the Declaration of Helsinki protocol.
Growth inhibition assay
The growth inhibitory effect of Cerulenin in MM cell lines,
primary MM cells, PBMNC and normal plasma cells was assessed
by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodi-
um bromide (MTT; Sigma) dye absorbance. Cells were plated in
96-well microtitre plates at a density of 2–3 · 10
4 cells per well,
and each plate was incubated for 24 and/or 48 h, with MTT added
to each well for the last 4 h. The absorbance of each well was
measured at 570/630 nm using a spectrophotometer (Molecular
Devices, Sunnyvale, CA, USA).
To measure proliferation of MM cells and BMSC, the rate of
DNA synthesis was measured, as described previously (Hideshima
et al, 2000). MM cells were incubated in 96-well culture plates
(Costar, Cambridge, MA, USA) in the presence of Cerulenin and/
or recombinant cytokines IL-6 or IGF-1 for 48 h at 37 C. Cells
were pulsed with 18Æ5 kBq/well of [
3H]-thymidine ([
3H]-TdR;
Perkin Elmer, Boston, MA, USA) during the last 8 h of culture,
harvested onto glass ﬁlters with an automatic cell harvester
(Cambridge Technology, Cambridge, MA, USA), and counted
using the LKB Betaplate scintillation counter (Wallac, Gaithers-
burg, MD, USA). MTT and
3H uptake analysis were performed in
triplicate or quadruplicate cultures.
Immunoblotting
The MM cells were harvested, washed twice with PBS, and lysed
using lysis buffer: 50 mmol/l Tris–HCl (pH 7Æ4), 150 mmol/l NaCl,
1% Nonidet P-40, 10 mmol/l sodium pyrophosphate, 5 mmol/l
EDTA, 1 mmol/l EGTA, 2 mmol/l Na3VO4, 5 mmol/l NaF,
1 mmol/l phenylmethylesulphonyl ﬂuoride (PMSF), 5 lg/ml leu-
peptin and 5 lg/ml aprotinin, as described previously (Hayashi
et al, 2002). Subcellular proteins were extracted from 2 · 10
7
viable cells using a mitochondria isolation kit (Pierce, Rockford, IL,
USA). The whole cell lysates or fractionated proteins (20 lg per
lane) were subjected to sodium dodecyl sulphate–polyacrylamide
gel electrophoresis, transferred to nitrocellulose membranes (Bio-
Rad Laboratories, Hercules, CA, USA), and immunoblotted with
anti-PARP, caspase-8, caspase-3, caspase-9, AIF, voltage-depen-
dent anion channel (VDAC), ASK1, GRP78/Bip, IRE1a, p-JNK,
JNK, p-ATF-2, p-c-Jun and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) (Cell Signaling, Beverly, MA, USA); as well as
with anti-a-tubulin antibodies (Abs) (Santa Cruz Biotechnology,
Inc. Santa Cruz, CA, USA), anti-Fatty Acid Synthase Abs (BD Bio-
science, San Jose, CA, USA), anti-Endo G (ProSci Inc., Poway, CA,
USA) and anti-XBP-1 (Abcam, Inc. Cambridge, MA, USA) Abs.
Flow cytometric analysis
For detection of apoptotic cells, mitochondrial protein staining
was performed with pycoerythrin-labeled anti-Apo2Æ7 antibody
(Immunotec, Marseille, France). Cells were treated with various
concentrations of Cerulenin for 24 h, washed with PBS, and then
incubated with Apo2Æ7 for 30 min. Apo2Æ7 staining was analysed
using the RXP cytomics software on an Epics ﬂow cytometer
(Coulter Immunology, Hialeah, FL, USA).
Immunocytochemistry
Cytospins of cells were prepared on glass slides and ﬁxed with 50%
methanol/50% acetone at 4 C. The slides were blocked in PBS
with 5% FBS at room temperature (RT), and then incubated with
primary antibody overnight at 4 C. Fluorescein isothiocyanate
(FITC)-labeled secondary antibody reaction for 30 min was then
performed. Coverslips were mounted on the glass slides with
VectaShield antifade/4¢,6-diamidino-2-phenylindole (DAPI),
which were analysed by Nikon E800 ﬂuorescence microscopy
(Nikon Inc., Melville, NY, USA).
Statistical analysis
Statistical signiﬁcance of differences observed in drug-treated
compared with control cultures was determined using the Mann–
Whitney test. The minimal level of signiﬁcance was P <0 Æ05. All
statistical analyses were determined using GraphPad Prism
software (GraphPad Software, Inc. San Diego, CA, USA).
Isobologram analysis
The interaction between Cerulenin and Bortezomib, Melphalan,
and Doxorubicin was analysed using CalcuSyn software program
(Biosoft, Ferguson, MO, USA) to determine whether the combi-
nation was additive or synergistic, as described previously (Chou
& Talalay, 1984; Raje et al, 2004). This program is based upon the
Chou-Talalay method, which calculates a combination index (CI).
Analysis is performed based on the following equation: CI = (D)1/
(Dx)1 + (D)2/(Dx)2 + (D)1(D)2/(Dx)1(Dx)2, where (D)1 and
(D)2 are the doses of drug 1 and drug 2 that have x effect when
used in combination; whereas (Dx)1 and (Dx)2 are the doses of
drug 1 and drug 2 that have the same x effect when used alone. A
CI c. 1Æ1 represents the conservation isobologram and indicates
additive effects, whereas CI c. <0Æ9 indicates synergism.
Results
FAS expression in various cells
We ﬁrst examined baseline expression of FAS in various cells. FAS
protein was expressed in all MM cell lines (Fig 1A and B; lane 5),
as well as in primary tumour cells from MM patients (Fig 1B; lane
4, Fig 1C). Importantly, FAS expression was higher in both MM
cell lines and primary tumour cells than in normal plasma cells, as
assessed by Western blotting (Fig 1B) and conﬁrmed by immu-
nocytochemical analysis (Fig 1D).
Cerulenin inhibits growth of MM cells
We next examined the effect of FAS inhibition by Cerulenin
(C12H17NO3; Fig 2A) on growth of MM cells and normal cells,
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Cerulenin signiﬁcantly inhibited the growth of drug-sensitive
MM.1S, U266, RPMI8226, OPM1 and OPM2 MM cell lines, with
a 50% inhibitory concentration (IC50) at 24 h of 24Æ16, 22Æ7, 24Æ03,
37Æ03 and 21Æ53 lmol/l, respectively, and IC50 at 48 h of 12Æ59,
11Æ12, 17Æ08, 11Æ45 and 9Æ71 lmol/l respectively (Fig 2B and C).
Cerulenin also inhibited growth of Dex-resistant MM.1R, Mel-
resistant RPMI-LR5, Dox-resistant RPMI-Dox40 MM cell lines,
with IC50 at 24 h of 22Æ59, 86Æ21 and 33Æ29 lmol/l, and IC50 at 48 h
of 10Æ52, 22Æ73 and 16Æ52 lmol/l respectively (Fig 2B and C).
However, Cerulenin did not induce cytotoxicity in PBMNC and
normal plasma cells from three healthy volunteers (Fig 2E and F).
Importantly, Cerulenin induced dose-dependent cytotoxicity
against CD138 positive MM cells (IC50 at 24 h of 27Æ37 lmol/l)
isolated from three patients whose disease was refractory to
Dexamethasone, Melphalan, Thalidomide, or Bortezomib therapy
(Fig 2D). These results indicate that FAS inhibition by Cerulenin
selectively andpotently induces cytotoxicity inMM cell lines aswell
asprimary MMcells,even thoseresistant toconventional andnovel
therapy.
Cerulenin overcomes the growth stimulatory effects of
cytokines, and inhibits MM cell growth in culture with
BMSCs
It has been demonstrated that IL-6 and IGF-1 induce both growth
and inhibition of apoptosis in MM cells (Jourdan et al, 2000;
Mitsiades et al, 2002, 2004), therefore, we examined whether FAS
1     2     3     4     5     6     7    8    9   10   11   12   13   14   15   16   17   18
FAS
GAPDH
1     2     3     4     5
(A)
(C)
(D)
(B)
FAS
-tubulin
1      2      3      4      5      6      7      8
-tubulin
FAS
MM.1S
U266
FAS-FITC DAPI MERGE
Primary
MM cells
Normal
plasma
cells
x 1000
Fig 1. FAS expression in various cells. Cell lysates (20 lg) of MM cell lines (A), normal cells and MM cells (B), and patient cells (B; lane 4, C) were
immunoblotted with anti-FAS antibody. (A) FAS expression was detected in all MM cell lines: lane 1, U266; lane 2, MM.1S; lane 3, MM.1R; lane 4,
RPMI8226; lane 5, RPMI Dox40; lane 6, RPMI LR5; lane 7, OPM1; and lane 8, OPM2. (B) FAS expression level was compared in plasma cells and
MM cells (lane 1–3, normal plasma cells; lane 4, primary MM cells; lane 5, MM.1S). FAS protein was more highly expressed in MM.1S and primary
MM cells than in plasma cells. (C) FAS protein was expressed in all (18/18) primary MM cells. (D) FAS expression in MM cell lines, primary MM cells
and normal plasma cells was analysed by immunocytochemistry. FITC-labeled FAS, nuclear staining by DAPI, and combined staining (Merge) were
evaluated by ﬂuorescence microscopy (·1000). Green and blue signal show FAS-FITC and DAPI respectively. FAS protein in MM cells is most
abundant in the cytoplasm with only weak non-speciﬁc of nuclear membrane staining.
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Both IL-6 (10 ng/ml) and IGF-1 (50 ng/ml) triggered increased
growth in MM.1S and U266 cells, which was inhibited by
Cerulenin (P <0 Æ05) (Fig 3A and B). As we previously have
shown that the BM microenvironment confered growth and drug
resistance in MM cells (Hideshima et al, 2004), we next examined
the effect of FAS inhibition on MM cell growth in the BM milieu.
MM.1S and U266 cells were cultured for 48 h with or without
BMSC, in the presence or absence of Cerulenin. MM cell
adherence to BMSC enhanced [
3H]-thymidine uptake in MM
cells, which was inhibited by Cerulenin (P <0 Æ05) (Fig 3C). These
results indicate that Cerulenin also blocks the growth stimulatory
effect of the BM microenvironment on MM cells.
Cerulenin induces apoptosis via activation of
caspase-independent pathway
To analyse the mechanism of cytotoxicity triggered by Cerulenin
in MM cells, we next performed Apo2Æ7 analysis and immuno-
blotting in MM.1S and U266 cells. Cerulenin induced apoptosis
in a dose-dependent manner, evidenced by Apo2Æ7 analysis
(Fig 4A, Fig S1C). Cerulenin also triggers caspase -8, -9, -3, and
Fig 2. Cerulenin inhibits MM cell growth. (A) Chemical structure of Cerulenin. (B) MM.1S ( ), MM.1R (h), U266 ( ), RPMI8226. (d), RPMI LR5
(s), RPMI Dox40 (r), OPM1 ()) and OPM2 (*) cells were cultured for 24 or 48 h in the presence of Cerulenin. (C) IC50 of MM cell lines treated
with Cerulenin for 24 or 48 h. (D) Cerulenin inhibits growth of primary MM patient cells [#1 ( ), #2 (h), #3 ( ), n = 3]. (E) Cerulenin does not
affect viability of PBMNC derived from three healthy volunteers [#1 ( ), #2 (h), #3 ( ), n = 3]. (F) Cerulenin does not affect viability of plasma cells
derived from three healthy volunteers [#1 ( ), #2 (h), #3 ( ), n = 3]. Cell growth was assessed by MTT assay (B, C, D, E, F), and data represent
mean ± SD of triplicate cultures.
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the pan-caspase inhibitor Z-VAD-FMK blocked Cerulenin-
induced caspase and PARP cleavage in both MM.1S and U266
cells (Fig 4B, Fig S1A), it did not inhibit Cerulenin-triggered
apoptosis (Fig 4D, Fig S1C) and cell death (Fig 4C, Fig S1B).
During Cerulenin-induced apoptosis in MM cells, both AIF and
Endo G were signiﬁcantly released from the mitochondria to
cytosol in a time-dependent manner (Fig 4E). These results
suggest that Cerulenin triggers apoptosis, at least in part, via a
caspase-independent, AIF/Endo G pathway.
Cerulenin induces ER stress response via up-regulation
of GRP78, IRE1a, JNK pathway
As some reports have demonstrated that FAS inhibitor induced
ER stress response in tumour cells (Little et al, 2007), we next
examined whether FAS inhibition by Cerulenin triggers activa-
tion of GRP78, IRE1a, JNK pathway as an ER stress response in
MM cells. The ER stress inducer Tunicamycin signiﬁcantly up-
regulated Grp78, IRE1a, ASK1, JNK and XBP-1 in MM.1S cells
(Fig 5A). In addition, Cerulenin treatment also induced up-
regulation of Grp78, IRE1a and p-JNK, as well as its
downstream molecules p-ATF-2 and p-c-Jun (Fig 5A). Impor-
tantly, JNK inhibitor SP600215 signiﬁcantly blocks Cerulenin-
induced cytotoxicity in MM.1S and U266 cells, (P <0 Æ05)
(Fig 5B, Fig S2A). We also conﬁrmed that SP600215 markedly
inhibited JNK signaling pathway in MM.1S cells by Western
blotting (Fig 5E); however, it did not inhibit apoptosis and
caspase cleavage triggered by Cerulenin in both MM.1S
and U266 cells (Fig 5C and D, Fig S2B and C). In addi-
tion, combination pretreatment with JNK inhibitor and ZVAD-
FMK did not enhance the inhibitory effect of JNK inhibitor
alone, indicating that JNK activation is the major pathway
mediating Cerulenin-induced cytotoxicity in MM cells (Fig S3).
These results strongly indicate that targeting FAS by Cerulenin
induces ER stress response via up-regulation of Grp78/IRE1a/
JNK pathway, associated with JNK-dependent, non-apoptotic
cell death in MM cells.
Cerulenin combined with Bortezomib, Melphalan, or
Doxorubicin induces synergistic cytotoxicity against MM
cells
We further examined whether Cerulenin enhances the growth
inhibitory effect of other conventional agents in MM cells. MM.1S,
U266, and primary MM cells were cultured for 24 h with
Bortezomib (0–3Æ75 nmol/l), Melphalan (0–10 lmol/l) or Doxo-
rubicin (0–400 nmol/l) combined with Cerulenin (0–25 lmol/l).
Cerulenin enhanced growth inhibition triggered by Bortezomib,
Melphalan and Doxorubicin, as analysed by MTT assay (Fig 6, Fig
S4). Next, we analysed the interaction between Cerulenin and
these agents by isobologram analysis using CalcuSyn software
program (Raje et al, 2004). Based upon the Chou-Talalay method
to calculate the CI, we showed synergistic cytotoxic effects between
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Fig 3. CeruleninovercomestheprotectiveeffectsofIL-6,IGF-1andBMSCsonMMcellgrowth.(A,B,C)MM.1SandU266cellswereculturedfor48 h
withtheindicatedconcentrations[0 lmol/l(h),3Æ15 lmol/l( )6Æ25 lmol/l( ),12Æ5 lmol/l( )]ofCerulenin,inthepresenceorabsenceofIL-6(1or
10 ng/ml: A), IGF-1 (10 or 50 ng/ml: B), or BMSC (C). Cell growth was assessed by [
3H]-thymidine uptake. Cerulenin inhibits MM cell growth and
overcomesthestimulatingeffectofIL-6(A)orIGF-1(B)(P <0 Æ05),andBMSC(P <0 Æ05)(C).Valuesrepresentmean ± SD ofquadruplicatecultures.
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maximum CI of 0Æ567, 0Æ188 and 0Æ529, respectively, in MM.1S
cells; 0Æ63, 0Æ404 and 0Æ079, respectively, in primary MM cells;
and 0Æ879, 0Æ591, and 0Æ301, respectively, in U266 cells. These
data demonstrate that these combination therapies enhance
Cerulenin- induced cytotoxicity synergistically in MM cells, due
to the fact that these agents induce caspase-dependent apoptosis
whereas Cerulenin triggers primarily caspase-independent apop-
tosis.
Discussion
This report demonstrated that FAS inhibition by Cerulenin
induced cytotoxicity in drug-sensitive and drug-resistant MM cell
(A)
(B)
(C) (E)
(D)
Fig 4. Cerulenin induces apoptosis via activation of caspase-independent pathway. (A) MM.1S cells were cultured for 24 h with Cerulenin at the
indicated doses. Induction of apoptosis by Cerulenin was determined by Apo2Æ7 staining and ﬂow-cytometric analysis. (B) MM.1S cells were cultured
with Cerulenin (50 lmol/l) for the indicated times (left panel), and preincubated with or without Z-VAD-FMK (50 lmol/l) for 1 h prior to treatment
withCeruleninfor12 hattheindicateddoses(rightpanel).Totalcelllysates(20 lg/lane)weresubjectedtoWesternblottingusinganti-caspase-8,-9,-3,
PARP, and a-tubulin Abs. FL, CF indicate the full length and cleaved form, respectively. (C, D) MM.1S cells were treated with the indicated dose of
Cerulenin for 24 h, with or without Z-VAD-FMK (25 lmol/l or 50 lmol/l) 1 h pretreatment. Cytotoxicity was determined by MTT assay (C). Values
represent mean ± SD of quadruplicate cultures. The percentage of apoptotic cells was determined by ﬂow-cytometric analysis for APO2Æ7 staining (D).
(E)MitochondrialproteinsAIFandEndoGwerereleasedintothecytosolicfractionfrommitochondriaafterCerulenin(50 lmol/l)treatmentinMM.1S
cells. Total cell lysates (20 lg/lane) were subjected to Western blotting using anti-AIF, Endo G, VDAC and a-tubulin Abs.
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21Æ53–86Æ21 lmol/l. In contrast, we observed no cytotoxicity
against PBMNC and normal plasma cells, indicating selective and
potent cytotoxicity against MM tumour cells. Immunoblot and
immunocytochemical analysis revealed that FAS protein was more
highly expressed in all MM cell lines and primary MM cells than in
normal plasma cells, consistent with prior reports of FAS
overexpression in cancer cells (Omura, 1976; Milgraum et al,
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Menendez & Lupu, 2007) and further suggesting that it represents
a novel therapeutic target in MM.
The BM microenvironment confers drug resistance in MM cells
via at least two different mechanisms: (i) cell adhesion mediated
drug resistance (CAM-DR) through adhesion of MM cells to
ﬁbronectin and BMSC; and (ii) activation of phosphatidylinositol
3-kinase (PI3-K)/Akt and/or Janus kinase 2 (JAK2)/signal trans-
ducers and activators of transcription 3 (STAT3) signaling due to
high levels of cytokines in the BM milieu (such as IL-6 and IGF-1)
(Damiano et al, 1999; Hazlehurst et al, 2000; Hideshima et al,
2001, 2004). Importantly, treatments targeting the BM microen-
vironment as well as the MM cell can overcome drug resistance in
both preclinical and clinical studies (Mitsiades et al, 2004;
Hideshima et al, 2007). Our data indicate that Cerulenin over-
comes the survival and growth advantages conferred by IL-6, IGF-
1 and BMSC, strongly suggesting its utility to overcome conven-
tional drug resistance in MM.
Although caspases are the key executors of apoptosis, recent
studies suggest that caspase activation is not the sole pathway for
inducing apoptosis or necrosis (Jaattela & Tschopp, 2003;
Abraham & Shaham, 2004; Lockshin & Zakeri, 2004). For
example, caspase-independent cell death in MM cells is triggered
by AS2O3 and inosine monophosphate dehydrogenase inhibitor
VX-944 treatment (McCafferty-Grad et al, 2003; Ishitsuka et al,
2005). The AIF/Endo G pathway is a major caspase-independent
apoptotic cascade (Daugas et al, 2000; Ahn et al, 2004; Cande
et al, 2004; Cregan et al, 2004). In this pathway, enhanced Bcl-2
family expression induces mitochondrial membrane permeability,
thereby releasing AIF and Endo G from the mitochondria to the
cytosol and nucleus, with subsequent chromatin condensation and
cell death. The present study showed that MM cell apoptosis
triggered by Cerulenin was primarily mediated via a caspase-
independent pathway. Although cleavage of caspase -8,-9,-3 and
PARP was induced by Cerulenin treatment, Z-VAD-FMK did not
block completely Cerulenin-induced apoptosis and cell death.
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mitochondria to cytosol during Cerulenin-induced apoptosis.
These results suggest that Cerulenin triggers apoptosis, at least in
part, via a caspase-independent AIF/Endo G pathway, with only
modest activation of caspase -8,-9,-3 and PARP. As most
conventional and novel drugs induce apoptosis in MM cells via
activation of caspases, we next examined the effect of combining
Cerulenin and other drugs. Cerulenin combined with Bortezomib,
Melphalan or Doxorubicin triggered synergistic MM cell cytotox-
icity, indicating that it may be useful to sensitize or overcome drug
resistance.
The ER stress response is a choreographed series of cellular
events activated by speciﬁc insults that result in altered ER
function (Kaufman, 2004; Xu et al, 2005). The combined effect of
this response is the activation of genes associated with an
adaptation response. Upon prolonged stress, the adaptation
mechanism of the ER stress response is saturated, resulting in cell
death. Several studies have demonstrated important associations
between lipid synthesis pathways and the ER stress response (Cox
et al, 1997; van der Sanden et al, 2004; Sriburi et al, 2004;
Tessitore et al, 2004). Inhibition of phospholipid synthesis,
especially that of phosphatidylcholine, induces ER stress-related
pathways (van der Sanden et al, 2004). Fatty acid synthesis in
general, and FAS activity in particular, occurs in the ER (Swinnen
et al, 2003). Importantly, because of the direct connection
between FAS activity and phospholipid synthesis, previous
reports demonstrated that pharmacologic blockade of FAS
activity induced ER stress in tumour cells via activation of
PERK/eIF2a and IRE1a/XBP-1 pathways (Swinnen et al, 2003;
Little et al, 2007). In addition, Nakamura et al (2006) reported
that activation of the ER stress pathway was associated with
survival of MM cells, as they contained a well-developed ER due
to M-protein production. Our data and other reports indicated
that increased FAS expression in tumour cells is important for ER
function; and conversely, suggest a role for ER stress in the
antitumour effects of FAS inhibitors. The present study showed
that Cerulenin treatment induced upregulation of Grp78, IRE1a
and p-JNK, as well as its downstream molecules p-ATF-2 and p-
c-Jun. IRE1a can activate the ASK1/JNK mitogen-activated
protein kinase pathway (Urano et al, 2000; Xu et al, 2005; Li
et al, 2006), and activation of JNK is a common response to
many forms of stress known to inﬂuence the cell-death machin-
ery (Davis, 2000). Although studies show that multiple pathways
can contribute to ER-stress-induced apoptosis (Li et al, 2006),
the mechanisms by which unresolved ER stress causes cell death
are not fully characterized (Szegezdi et al, 2006; Zhao &
Ackerman, 2006).
Bandyopadhyay et al (2006) proposed a model for apoptotic
signaling in which inhibition of FAS leads to accumulation of
malonyl-CoA, which in turn inhibits carnitine palmitoyltransfer-
ase-1 (CPT-1) and results in up-regulation of ceramide, followed
by induction of the proapoptotic genes BNIP3, tumour necrosis
factor (TNF)-related apoptosis-inducing ligand (TNFSF10), and
death-associated protein kinase 2 (DAPK2).BNIP3 not only
induces apoptotic cell death, but also is implicated in necrosis and
autophagy (Vande Velde et al, 2000; Daido et al, 2004). TNFSF10
has been shown to induce apoptosis in a wide range of
transformed cells (Kelley & Ashkenazi, 2004). In addition, a human
single-chain fragment variable (HW1) antibody against TRAIL
receptor 2 induced autophagic cell death predominantly via the
JNK pathway in a caspase-independent manner (Park et al, 2007).
DAPK2 is associated with ceramide-mediated apoptosis (Pelled
et al, 2002; Yamamoto et al, 2002), but also induces another cell
death pathway mediating autophagic or type II cell death (Inbal
et al, 2002; Bialik & Kimchi, 2004) without caspase activation
(Inbal et al, 2002). Our data and others suggest that inhibition of
FAS by Cerulenin activates multiple death signal pathways in MM
cells, including caspase-independent apoptosis and JNK dependent
non-apoptotic cell death. JNK and its downstream molecules ATF-
2 and c-Jun induce apoptosis in various tumours (Bossy-Wetzel
et al, 1997; Podar et al, 2007). Moreover, caspase-independent JNK
activation promotes autophagic cell death induced by TNF-a (Jia
et al,2006)andotherchemicals(Borselloet al,2003;Yuet al,2004;
Park et al, 2007). JNK can activate the mitochondrial pathway
including AIF, Endo G, cytochrome C and Smac (Weston & Davis,
2007). However, the exact role of c-Jun in mediating cell
differentiation, growth, survival and apoptosis is not fully under-
stood (Jochum et al, 2001; Vogt, 2001).
In summary, our data showed that inhibition of FAS by
Cerulenin induced primarily caspase-independent apoptosis via
upregulation of AIF/Endo G pathway, and JNK-dependent cell
death in MM cells. This report demonstrated that inhibition of
FAS had anti-tumour activity against MM cells, identifying FAS as
a novel therapeutic target. Taken together, our data provide the
preclinical rationale for clinical trials targeting FAS to improve
patient outcome in MM.
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Supplementary material
The following supplementary material is available for this article
online:
Fig S1. Cerulenin induces apoptosis in U266 cells. (A) U266
cells were cultured with Cerulenin (50 lmol/l) for the indicated
times, with or without Z-VAD-FMK (50 lmol/l) for 1 h pretreat-
ment. Total cell lysates (20 lg/lane) were subjected to Western
blotting using anti-caspase -8, -9, -3, PARP and a-tubulin Abs. FL,
CF indicated as full length and cleaved form, respectively. (B, C)
U266 cells were treated with indicated dose of Cerulenin for 24 h,
with or without Z-VAD-FMK (25 or 50 lmol/l) 1 h pretreatment.
Cytotoxicity was determined by MTT assay (B). Values represent
mean ± SD of quadruplicate cultures. The percentage apoptotic
cells was determined by ﬂow-cytometric analysis for APO2
.7
staining (C).
Fig S2. JNK inhibitor blocks Cerulenin-induced cytotoxicity in
U266 cells. (A, B) U266 cells were cultured with indicated dose of
Cerulenin for 24 h, with or without JNK inhibitor SP600215 (5 or
10 lmol/l) pretreatment for 1 h. Cytotoxicity was determined by
MTT assay (A). Values represent mean ± SD of quadruplicate
cultures. JNK inhibitor signiﬁcantly blocks Cerulenin-induced
cytotoxicity (P < 0.05). The percentage apoptotic cells was
determined by ﬂow-cytometric analysis for APO2
.7 staining (B).
(C) Total cell lysates (20 lg/lane) were subjected to Western
blotting using anti-caspase -8, -9, -3, PARP and a-tubulin Abs. FL,
CF indicated as full length and cleaved form, respectively.
Fig S3. Analysis of inhibition by JNK inhibitor SP600215 and/or
ZVAD-FMK in MM cells. (A, B) MM.1S and U266 cells were
cultured with indicated dose of Cerulenin for 24 h, with or
without JNK inhibitor SP600215 (10 lmol/l) and/or ZVAD-FMK
(50 lmol/l) pretreatment for 1 h. Cytotoxicity was determined by
MTT assay. Values represent mean ± SD of quadruplicate cul-
tures. Although ZVAD-FMK does not affect cytotoxicity by
Cerulenin, JNK inhibitor signiﬁcantly blocks Cerulenin-induced
cytotoxicity (P < 0.05).
Fig S4. Cerulenin enhances Bortezomib, Melphalan, and
Doxorubicin-induced cytotoxicity in U266 cells. U266 cells were
cultured for 24 h with indicated concentrations of Bortezomib
(A), Melphalan (B), and Doxorubicin (C) [control media (h),
1.25 nmol/l Bortezomib ( ), 2.5 nmol/l Bortezomib ( ),
3.75 nmol/l Bortezomib ( ); control media (h), 2.5 lmol/l
Melphalan ( ), 5 lmol/l Melphalan ( ), 10 lmol/l Melphalan
( ); control media (h), 100 nmol/l Doxorubicin ( ), 200 nmol/l
Doxorubicin ( ), 400 nmol/l Doxorubicin ( )], in the presence or
absence of Cerulenin (0–25 lmol/l). Cell growth was assessed by
MTT assays. Data represent mean (±SD) of triplicate cultures.
Combination index (CI) of Cerulenin and these agents was
analysed using CalcuSyn software.
The material is available as part of the online article from: http://
www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2141.2008.
07114.x
(This link will take you to the article abstract).
Please note: Blackwell Publishing are not responsible for the
content or functionality of any supplementary materials supplied
by the authors. Any queries (other than missing material) should
be directed to the corresponding author for the article.
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